

**Cystic
Fibrosis Trust**



Clinical Trials Accelerator Platform

Impact Report 2024

Uniting for a life unlimited

Clinical Trials Accelerator Platform

Impact Report 2024



Cystic Fibrosis Trust launched the Clinical Trials Accelerator Platform (CTAP) in 2017 to help more people with CF to access clinical trials and to support the people who run trials (sponsors) to deliver a wide range of trials in the UK.

Since then, we've supported 70 studies, helped thousands of people take part, and significantly reduced the time it takes to get a trial set up.

The past year has been very successful for CTAP. This report highlights our achievements over the last 12 months (March 2023–February 2024) and our overall impact since CTAP began.

Our network of clinical trial centres

CTAP supports a network of 25 CF centres and funds 25 CF trial coordinators across the UK.

CTAP centres reach approximately 90% of people with CF living in the UK. Our dedicated CF trial coordinators make it easier for trials to be set up and delivered at their centres.

Within the CTAP network, we have several initiatives to help us expand the number of people with CF who can take part in clinical trials.


CTAP Championship Scheme

Through this new scheme, CTAP trial coordinators are working with regional CF centres to inform them of clinical trial opportunities and how to refer their patients for trial participation.




Regional clinical trial networks

In addition to the established London regional CTAP network, we are setting up additional CTAP regional networks across Scotland, south-west England, and north-west England. These networks will support centres to refer patients for trial participation, expanding the number of people able to take part in clinical trials outside of their local CF centre.



Our impact this year




2,951 people with CF have been screened (2,515 adults; 436 children)

2,151 people with CF have taken part in a CTAP supported study (1,872 adults; 277 children)



As CF research has evolved, so has our portfolio of CTAP supported studies, including the recent addition of the **NIHR CF BioResource project**.

This project is aiming to create a register of people with CF who have agreed to be contacted about research based on their genetic make-up.




More than **1,000** people have enrolled onto the CF BioResource project including **685** people over the last year.

Our impact since CTAP began



Since CTAP's launch, study set-up times have decreased by **over 70%** – that's more than 11 weeks.

Participants since the launch of CTAP in 2017:




CTAP study portfolio


To date, 70 studies have been supported by CTAP. The studies in our portfolio have included a range of trial types, phases, and a variety of therapeutic areas.

Studies by area


Total number of studies = 70



Studies by phase



Studies by sponsor type



Interventional studies (phase 1-4 and non-drug intervention studies) look at a drug, behaviour change, or device that is intended to treat CF or symptoms of CF.

Non-interventional studies involve one-time samples or participant observation over time.